Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cannabis Science Issues CBN Patent and R&D Guidance

By Drug Discovery Trends Editor | May 22, 2014

Cannabis Science Inc., a U.S. company specializing in cannabis formulation-based drug development, issued CBN patent and R&D guidance for the 2nd quarter of 2014.
 
To support its existing CBN patent, the company delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer’s disease. 
 
Earlier this year the company raised funds to facilitate Cannabis Science’s R&D activities that will include production of pharmaceutical grade cannabis-based formulations to be developed for variety of illnesses, to continue moving forward its clinical observational studies and to initiate pre-clinical work on the company’s new product to address neurobehavioral disorders. 
 
“Cannabis Science has made solid progress so far this year. I am proud to be a part of this team and I am very positive about our future,” stated Robert Kane, CFO of Cannabis Science.
 
In conjunction, the company is discussing the initiation of additional clinical studies using pharmaceutical grade cannabis in proprietary, topical and orally administered applications to various skin conditions including skin cancer work to be conducted in several geographic areas in collaboration with multiple potential partners. 
 
The company is finalizing discussions with further research groups to ensure timely completion of the planned development. Following the completion of the toxicity and the pre-clinical efficacy studies the company plans to proceed into clinical studies during the next year. Work has also been initiated on the formulations and negotiations are underway to establish several commercial partnerships in this area.
 
Date; May 22, 2014
Source: Cannabis Science

Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE